AgomAb Therapeutics N.V. American Depositary Shares
NASDAQ:AGMBBiotechnology
+$0.25 today
- Market cap
- $286.62M
- Beta
- 2.62
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$1.28
Volume 0.13M
Average 0.14M
AGMB Total Debt
Short-term and long-term borrowings combined.
AgomAb Therapeutics N.V. American Depositary SharesNASDAQ: AGMB
Total Debt · Q3 FY2025 · quarter ended Sep 2025
Total debt of €1.33M in Q3 FY2025
Q3 FY2025 total debt was €1.33M.
Context
- Total debt amounted to 0.8% of total assets at the end of Q3 FY2025.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Debt history
Currency unavailable · from the balance sheet
No Total Debt data reported for this period type.
Total Debt vs competitors
How AGMB compares with its peers on the latest reported figures
- Peers report in different currencies, so total debt is compared through growth and share of total assets rather than absolute size.
- Total debt amounts to 0.8% of total assets for AGMB, versus a peer median of 3.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $277.36M USD | +1680.8% | -10.1% | 84.1% | |
ALMSAlumis Inc. Common Stock | Jun 2026 | $36.43M USD | -6.1% | +174.8% | 6.5% |
| Mar 2026 | $1.99M USD | -20.1% | +45.7% | 1.0% | |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | Sep 2025 | €1.33M EUR | — | — | 0.8% |
| Mar 2026 | $692K USD | +134.6% | -58.7% | 1.1% | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding AGMB) | — | +64.3% | +17.8% | 3.8% | |
Competitors are the stored peer set for AGMB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
AgomAb Therapeutics N.V. American Depositary Shares
NASDAQ:AGMB
Intrinsic Alpha fair value
Locked
Current Price
$5.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.